Medpace Holdings, Inc.
Key Metrics
- Previous Close
- $646.87
- 52-Week Range
- $373.00 – $693.97
- Market Cap
- $17.73B
- P/E (TTM)
- 35.20
- EPS (TTM)
- 18.01
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 30.31
- PEG Ratio
- 3.36
- Return on Equity
- 117.88%
- Return on Assets
- 18.71%
- Gross Margin
- 72.24%
- Operating Margin
- 21.39%
- Profit Margin
- 18.24%
- Current Ratio
- 0.83
- Debt/Equity
- 0.29
- Total Debt
- $171.46M
- Free Cash Flow
- $497.78M
- Revenue Growth
- 8.50%
- Earnings Growth
- 25.40%
- Enterprise Value
- $17.56B
Market Snapshot
About
Medpace Holdings, Inc. is a global contract research organization (CRO) providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company offers full-service clinical development support from Phase I through Phase IV, along with laboratory and imaging services.